Norfloxacin with itopride versus norfloxacin alone in secondary prophylaxis of spontaneous bacterial peritonitis: a randomized trial
Abstract Background Bacterial translocation is considered the pathophysiological hallmark in the development of spontaneous bacterial peritonitis (SBP). Prokinetics can increase gastrointestinal (GIT) motility, reduce small bowel transit time, decrease bacterial translocation, and the possibility of...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2021-05-01
|
Series: | Egyptian Liver Journal |
Subjects: | |
Online Access: | https://doi.org/10.1186/s43066-021-00106-7 |
id |
doaj-177bd5f308d246b8b6f4295229e16631 |
---|---|
record_format |
Article |
spelling |
doaj-177bd5f308d246b8b6f4295229e166312021-05-11T14:55:15ZengSpringerOpenEgyptian Liver Journal2090-62262021-05-011111710.1186/s43066-021-00106-7Norfloxacin with itopride versus norfloxacin alone in secondary prophylaxis of spontaneous bacterial peritonitis: a randomized trialAfaf Y. M. Younes0Sherief Abd-Elsalam1Gehan F. Attia2Mona A. H. Shehata3Department of Tropical Medicine and Infectious Diseases, Faculty of Medicine, Tanta UniversityDepartment of Tropical Medicine and Infectious Diseases, Faculty of Medicine, Tanta UniversityDepartment of Clinical Pathology, Faculty of Medicine, Tanta UniversityDepartment of Tropical Medicine and Infectious Diseases, Faculty of Medicine, Tanta UniversityAbstract Background Bacterial translocation is considered the pathophysiological hallmark in the development of spontaneous bacterial peritonitis (SBP). Prokinetics can increase gastrointestinal (GIT) motility, reduce small bowel transit time, decrease bacterial translocation, and the possibility of SBP. The aim of this work was to compare the effectiveness and safety of itopride and norfloxacin versus norfloxacin only in secondary prophylaxis for cirrhotic ascitic patients with spontaneous bacterial peritonitis. Results Regarding the baseline clinical manifestations and laboratory investigations, there was no significant difference between both groups. The incidence of a recurrent SBP in group I, who had received itopride plus norfloxacin, reduced with a significant difference than other group II (P=0.018). The median time for recurrence of SBP was highly longer in group I than group II with a significant difference (P=0.042). Conclusions The combined usage of itopride with norfloxacin in patients with cirrhosis and ascites can decrease the occurrence of a recurrent SBP and significantly improve the survival of patients. Trial registration ClinicalTrials.gov Identifier: NCT04161768 .https://doi.org/10.1186/s43066-021-00106-7Spontaneous bacterial peritonitisCirrhosisAscitesProkineticsNorfloxacinItopride |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Afaf Y. M. Younes Sherief Abd-Elsalam Gehan F. Attia Mona A. H. Shehata |
spellingShingle |
Afaf Y. M. Younes Sherief Abd-Elsalam Gehan F. Attia Mona A. H. Shehata Norfloxacin with itopride versus norfloxacin alone in secondary prophylaxis of spontaneous bacterial peritonitis: a randomized trial Egyptian Liver Journal Spontaneous bacterial peritonitis Cirrhosis Ascites Prokinetics Norfloxacin Itopride |
author_facet |
Afaf Y. M. Younes Sherief Abd-Elsalam Gehan F. Attia Mona A. H. Shehata |
author_sort |
Afaf Y. M. Younes |
title |
Norfloxacin with itopride versus norfloxacin alone in secondary prophylaxis of spontaneous bacterial peritonitis: a randomized trial |
title_short |
Norfloxacin with itopride versus norfloxacin alone in secondary prophylaxis of spontaneous bacterial peritonitis: a randomized trial |
title_full |
Norfloxacin with itopride versus norfloxacin alone in secondary prophylaxis of spontaneous bacterial peritonitis: a randomized trial |
title_fullStr |
Norfloxacin with itopride versus norfloxacin alone in secondary prophylaxis of spontaneous bacterial peritonitis: a randomized trial |
title_full_unstemmed |
Norfloxacin with itopride versus norfloxacin alone in secondary prophylaxis of spontaneous bacterial peritonitis: a randomized trial |
title_sort |
norfloxacin with itopride versus norfloxacin alone in secondary prophylaxis of spontaneous bacterial peritonitis: a randomized trial |
publisher |
SpringerOpen |
series |
Egyptian Liver Journal |
issn |
2090-6226 |
publishDate |
2021-05-01 |
description |
Abstract Background Bacterial translocation is considered the pathophysiological hallmark in the development of spontaneous bacterial peritonitis (SBP). Prokinetics can increase gastrointestinal (GIT) motility, reduce small bowel transit time, decrease bacterial translocation, and the possibility of SBP. The aim of this work was to compare the effectiveness and safety of itopride and norfloxacin versus norfloxacin only in secondary prophylaxis for cirrhotic ascitic patients with spontaneous bacterial peritonitis. Results Regarding the baseline clinical manifestations and laboratory investigations, there was no significant difference between both groups. The incidence of a recurrent SBP in group I, who had received itopride plus norfloxacin, reduced with a significant difference than other group II (P=0.018). The median time for recurrence of SBP was highly longer in group I than group II with a significant difference (P=0.042). Conclusions The combined usage of itopride with norfloxacin in patients with cirrhosis and ascites can decrease the occurrence of a recurrent SBP and significantly improve the survival of patients. Trial registration ClinicalTrials.gov Identifier: NCT04161768 . |
topic |
Spontaneous bacterial peritonitis Cirrhosis Ascites Prokinetics Norfloxacin Itopride |
url |
https://doi.org/10.1186/s43066-021-00106-7 |
work_keys_str_mv |
AT afafymyounes norfloxacinwithitoprideversusnorfloxacinaloneinsecondaryprophylaxisofspontaneousbacterialperitonitisarandomizedtrial AT sheriefabdelsalam norfloxacinwithitoprideversusnorfloxacinaloneinsecondaryprophylaxisofspontaneousbacterialperitonitisarandomizedtrial AT gehanfattia norfloxacinwithitoprideversusnorfloxacinaloneinsecondaryprophylaxisofspontaneousbacterialperitonitisarandomizedtrial AT monaahshehata norfloxacinwithitoprideversusnorfloxacinaloneinsecondaryprophylaxisofspontaneousbacterialperitonitisarandomizedtrial |
_version_ |
1721443832704270336 |